enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a pu
(Financial Post, 2025-11-13T05:29:42Z)